TNFRSF19 and central nervous system cancer: Within the TCGA group, gliomas showing high TNFRSF19 levels exhibited notably increased expression of 28 immune checkpoint proteins, such as PD-L1, and reduced expression of six immune checkpoint genes when compared to those with low TNFRSF19 levels (P < 0.05, Fig. 8A).